Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics has signed collaboration agreement with the National Institute of Health to identify microRNAs involved in the progression of the human immunodeficiency virus, which may be used as potential drug targets.
Subscribe to our email newsletter
Rosetta Genomics has access to the majority of known human and viral microRNAs. From this strong intellectual property position, the company has developed highly sensitive, proprietary technologies to detect and quantify microRNAs.
Leveraging Rosetta Genomics’s extensive know-how in microRNAs and proprietary technologies, this collaboration will seek to determine the role of microRNAs in HIV viral replication, and their potential to act as novel drug targets for future therapy.
Zvi Bentwich, chief scientist of Rosetta Genomics, said: “Having the opportunity to work with the National Institute of Health (NIH) on this important collaboration is a reflection on our leading capabilities and know how in this field.”